Evaluation of the AusDiagnostics MT CRE EU assay for the detection of carbapenemase genes and transferable colistin resistance determinants mcr-1/-2 in MDR Gram-negative bacteria

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Objectives To evaluate the AusDiagnostics MT CRE EU assay for the detection of carbapenemase and acquired colistin resistance genes in Gram-negative bacteria. Methods The assay allows the detection of bla KPC, bla OXA-48-like, bla NDM, bla VIM, bla IMP, bla SIM, bla GIM, bla SPM, bla FRI, bla IMI, bla GES (differentiating ESBL and carbapenemase variants), bla SME and mcr-1/-2. It was evaluated against a panel of isolates including Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. retrospectively (n = 210) and prospectively (n = 182). Results The CRE EU assay was able to detect 268/268 carbapenemase genes, with 239 belonging to the 'big five' families (KPC, OXA-48-like, NDM, VIM and IMP) and 29 carbapenemase genes of the SIM, GIM, SPM, FRI, IMI, SME and GES families. It could distinguish between ESBL and carbapenemase variants of GES. It also allowed detection of mcr-1/-2 colistin resistance genes on their own or in isolates co-producing a carbapenemase. Conclusions The AusDiagnostics MT CRE EU assay offered wide coverage for detection of acquired carbapenemase genes. It required minimal hands-on time and delivered results in less than 4 h from bacterial culture.

Original languageEnglish
Pages (from-to)3355-3358
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume73
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Dive into the research topics of 'Evaluation of the AusDiagnostics MT CRE EU assay for the detection of carbapenemase genes and transferable colistin resistance determinants mcr-1/-2 in MDR Gram-negative bacteria'. Together they form a unique fingerprint.

Cite this